Hefei Lifeon Pharmaceutical Co Ltd

Hefei Lifeon Pharmaceutical Co Ltd maintains a relatively strong liquidity position, with a current ratio of 2.03, indicating that it has more than double the current assets to cover its current liabilities. However, the company's liquidity risk is assessed as medium, and its net cash position is negative after subtracting total debt, suggesting potential short-term cash flow constraints.

In terms of profitability, the company's return on equity (ROE) is 2.78%, and its return on assets (ROA) is 1.89%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These figures suggest that the company is generating modest returns relative to its equity and asset base.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks, particularly in the Chinese pharmaceutical sector.

The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The absence of capital expenditure data beyond the current year also limits the ability to assess long-term investment plans.

The company's risk profile includes a low dilution potential, with no significant dilution sources identified in the available data. However, the presence of long-term debt and the negative net cash position suggest that the company may need to raise additional capital in the future, which could lead to share dilution.

Recent events and filings are not detailed in the available data, so it is not possible to assess the company's recent strategic moves or operational developments. Investors should monitor the company's upcoming filings and earnings reports for more insight into its performance and strategy.

Hefei Lifeon Pharmaceutical Co Ltd (003020.SZ) has undergone a significant update to its corporate taxonomy, with its primary activity now explicitly classified as "Pharmaceuticals" and its economic sector identified as "Healthcare." This structural clarification, marked as a medium-severity change, establishes the foundational context for analyzing the company’s operational focus within the broader healthcare industry. Concurrently, the firm’s risk profile has been formally assessed, revealing a "low" dilution risk. This assessment suggests that shareholders face minimal threat of equity value erosion through new share issuance, a critical factor for investors evaluating the stability of their ownership stakes in the company. In contrast, the liquidity risk assessment has been categorized as "medium." This indicates that while the company is not facing immediate distress, there are moderate considerations regarding the ease of trading its shares or accessing liquid capital, which may impact short-term trading dynamics and capital management strategies. These updates provide a clearer baseline for Hefei Lifeon Pharmaceutical’s financial and operational standing. With no current analyst coverage, index memberships, or disclosed top holders in the available data, these newly established risk and classification metrics serve as the primary indicators for understanding the company’s current market position and potential investment characteristics. [doc:003020.sz-ha-financials]

Debt-to-equity ratio of 0.05 is lower than the cohort median of 0.18, reflecting a conservative capital structure.

Cash conversion ratio of 1.65 outperforms the cohort median of 0.95, suggesting efficient working capital management.

Operating income grew 4.9% year-over-year, showing resilience in core profitability despite broader revenue fluctuations.

Return on equity of 2.8% falls below the pharmaceutical cohort median of 2.9%, indicating weaker capital efficiency.

The company faces medium liquidity risk, which could constrain operational flexibility during periods of financial stress.

Revenue ¥1.90B, −26,3% YoY; Operating income +6,5% YoY.

• ▍Revenue ¥1.90B, −26,3% YoY
• ▍Operating income +6,5% YoY
• ▍Net income +8,1% YoY
• ▍Free cash flow +129,6% YoY
• ▍Net margin 11.9%

Revenue ¥2.58B, +13,5% YoY; Operating income +24,7% YoY.

• ▍Revenue ¥2.58B, +13,5% YoY
• ▍Operating income +24,7% YoY
• ▍Net income +21,7% YoY
• ▍Free cash flow −169,1% YoY
• ▍Net margin 8.1%